Background: Quantitative susceptibility mapping (QSM) offers a consistent hemorrhage volume measurement independent of imaging parameters. Purpose: To investigate the magnetic susceptibility of intracerebral hemorrhage (ICH) as a quantitative measurement for monitoring treatment in hematoma patients. Study Type: Prospective. Population: Twenty-six patients with acute ICH were recruited and enrolled in treatment including surgery or medication (mannitol) for 1 week. Field Strength/Sequence: A 3D gradient echo sequence at 3.0T. Assessment: The hematoma volumes on computed tomography (CT) and QSM were calculated and used for correlation analysis. Magnetic susceptibility changes from pre-to posttreatment were calculated and compared to the National Institutes of Health stroke scale (NIHSS) measure of neurological deficit for each patient. Statistical Tests: Mean susceptibility values were calculated over each region of interest (ROI). A one-sample t-test was used to assess the changes of total volumes and mean magnetic susceptibility of ICH identified between pre-and posttreatment images (P < 0.05 was considered significant) and the Bland-Altman analysis with 95% limits of agreement (average difference, 61.96 SD of the difference). Regression of volume measurements on QSM vs. CT and fitted linear regression of mean susceptibility vs. CT signal intensity for hematoma regions were conducted in all patients. Results: Good correlation was found between hemorrhage volumes calculated from CT and QSM (CT volume 5 0.94*QSM volume, r 5 0.98). Comparison of QSM pre-and posttreatment showed that the mean ICH volume was reduced by a statistically insignificant amount from 5.74 cm 3 to 5.45 cm 3 (P 5 0.21), while mean magnetic susceptibility was reduced significantly from 0.48 ppm to 0.38 ppm (P 5 0.004).
I
ntracerebral hemorrhage (ICH) is a potentially devastating neurological injury representing 10-15% of stroke cases in the world each year. 1 Timely identification and management of this condition remained a challenge for clinicians, as numerous factors can present obstacles to achieving good functional outcomes. Most of the current management guidelines exist on medical evidence and consensus and these provide a framework for care. 2 ICH remains a disease usually treated with pharmaceuticals to relieve the pressure from the accumulation of blood. 3 In the acute setting, predictors of 30-day mortality include hematoma size, hematoma expansion, older patient age, coma, and hematoma location. 4, 5 Currently, greater than one-third of patients with ICH will not survive and only 20% of patients will regain functional independence. 1 This high rate of morbidity and mortality has prompted continued investigation of tools for the accurate localization and quantitative characterization of ICH to diagnose and evaluate the severity of ICH. A previous study reported 1uantitative susceptibility mapping (QSM) changes occurred in one subject when surgical intervention was involved. 6 Therefore, development of effective imaging biomarkers for monitoring of treatment has the potential to mitigate the economic and social burden of ICH. Magnetic resonance imaging (MRI) is increasingly being advocated as a comprehensive multimodal imaging approach for patients presenting with acute stroke symptoms. 7 Patients frequently undergo both MRI and computed tomography (CT) scanning as part of routine clinical care and research protocols. However, CT delivers potential risks of a high dose of radiation to the human body. Gradient echo (GRE) MRI has been shown to be more sensitive than CT for detecting ICH. [8] [9] [10] However, hypointensity in T 2 *-weighted GRE magnitude images is known to overestimate hematoma volume, as these images suffer from susceptibility artifacts that are highly dependent on imaging parameters, such as field strength, voxel size, and echo time. In contrast, QSM 9,11-14 based on GRE phase data can provide an accurate measurement of the hemorrhage volumes by removing blooming artifacts inherent in traditional T 2 *-weighted imaging. 15 QSM offers excellent image contrast by computing the spatial distribution of the underlying source of the phase contrast, ie, magnetic susceptibility. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Since iron is the major contributor to the magnetic susceptibility of hemorrhage, the highly paramagnetic blood lesions exhibit clear delineation within the surrounding relatively diamagnetic brain tissues. Thus, QSM may prove to be especially helpful when surgical treatments are applied to remove hemorrhagic fluid surrounded by soft tissues. Additionally, hematoma treatment presents a unique challenge due to different hemorrhagic products and nonuniform iron deposition within individual lesions. The blood degradation in hemorrhage has rarely been characterized on conventional MR images. During complex blood degradation in hemorrhage, hemoglobin changes through several forms. 26 The magnetic susceptibility progressively increases from slightly diamagnetic relative to cerebrospinal fluid (CSF) in oxyhemoglobin to paramagnetic in deoxyhemoglobin, methemoglobin, and hemosiderin. 27, 28 The sensitivity of QSM to such changes allows quantification of changes in the composition of the hematoma using MRI, 28 especially at the hyperacute and acute stages where timely treatment is critically important. It may be used to precisely assess treatment outcomes, providing useful quantitative information in hemorrhage patient management. Previous studies have shown that susceptibility changes in one subject when surgical intervention was performed. 6 Therefore, there is an ongoing need to establish a correlation between magnetic susceptibility of hemorrhages and clinical measures.
In the current study we sought to determine if the mean magnetic susceptibility pre-and posttreatment in ICH in QSM can be used as a biomarker to monitor treatment.
Materials and Methods

Patients
The study protocol was reviewed and approved by the Institutional Review Board and written informed consent was obtained from all participants prior to enrollment in the study. Twenty-six patients with acute ICH (58 6 15.1 years; 17 men, 9 women) were recruited from September 21, 2014, to March 1, 2015. All participants underwent imaging with MRI and CT scans as routine clinical ICH diagnosis. All hospitalized patients were actively enrolled in treatment including surgery and medication to decrease intracranial pressure and hemostatic therapy. After their conditions stabilized, posttreatment CT and MRI scans were performed on 21 patients. The interval between the pre-and posttreatment scans ranged from 5-8 days. Five patients were discharged before the posttreatment scans. Scores on the National Institutes of Health Stroke Scale (NIHSS) 29 were measured for each patient both preand posttreatment. All patients recovered and were discharged a few days after the posttreatment scans. Treatment details for individual patients are listed in Table 1 .
MRI and Data Reconstruction
All patients underwent brain MR examination on a 3T scanner (Signa HDxt, GE Healthcare, Waukesha, WI) equipped with an 8-channel head coil. Phase images with whole-brain coverage were acquired using a standard flow-compensated 3D spoiled gradient recalled (SPGR) sequence with the following parameters: echo time (TE) 1 /DTE/TE 16 , matrix size 5 256 3 256 3 66. The raw phase was processed by Laplacian-based phase unwrapping 30 and the normalized phase was calculated as
where n is the number of echoes. Note that i8 (TE > 20 msec) since previous study has reported that magnetic susceptibility in hematoma was independent of TE for echo times longer than 20 msec. 15 The normalized background phase was removed by V-SHARP. 31 QSM images were calculated using STAR-QSM (streaking artifact reduced quantitative susceptibility mapping).
32-34
Data Analysis
The hemorrhage volume was obtained by a semiautomated level set segmentation using MIPAV (Medical Image Processing, Analysis, and Visualization, NIH, Bethesda, MD). Lesions were segmented using regions of interest (ROIs) across multiple slices (3D ROI) on CT and QSM. j analysis was performed to assess the reliability of volume measurement between two independent radiologists (Y.Z., 20 years of experience; J.X., 33 years of experience). To access the sharpness between hematoma lesions and surrounding tissues, the line profiles were drawn on QSM images and tissue phase maps.
Statistical Analysis j statistics 35 were interpreted as indicating poor (j, <0), slight (0<j<0.2), fair (0.21<j<0.4), moderate (0.41<j<0.6), substantial (0.61<j<0.8), and almost perfect (0.81<j<1.0) observer agreement. 36 Mean susceptibility values were calculated over each ROI, and normalized relative to mean susceptibility of the CSF in the lateral ventricles without evidence of hemorrhages. A paired-sample ttest was used to assess the changes of total volumes and mean magnetic susceptibility of ICH identified between pre-and posttreatment images (P < 0.05 was considered significant) and the Bland-Altman analysis with 95% limits of agreement (average difference, 6 1.96 SD of the difference). Regression of volume measurements on QSM vs. CT and fitted linear regression of mean susceptibility vs. CT signal intensity for hematoma regions were conducted in all patients.
Results
Examples of T 2 *-weighted magnitude, R2*, QSM, and tissue phase images of an ICH patient are shown in Fig. 1 . The apparent size of the hematoma on T 2 *-weighted magnitude images increased substantially relative to the boundary defined on the image at TE 1 5 3.2 msec as blooming artifacts increased with echo time (Fig. 1A) . As a consequence, the boundary between the hematoma and surrounding tissues may be inaccurately defined on such images and on the R2* image (Fig. 1B) . The phase image makes the boundary Fig. 1D and by dash lines in Supplemental Fig. S1 . In addition, the geometric shape of the hematoma revealed by susceptibility maps at the longest TE 5 39.5 msec remains highly consistent with that at TE 5 3.2 msec.
The two radiologists had high agreement on measured hematoma volumes in all patients. The interobserver reliability was 95.4% according to j analysis. Figure 2 shows representative CT and QSM images pre-and posttreatment in a 67-year-old male patient. The boundary of the hematoma lesion on the corresponding axial location on CT and QSM are similar and are indicated by the red curves. Overall, the mean hemorrhage volume was 5.24 cm 3 measured on CT and 5.6 cm 3 on QSM. A linear 
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Month 2018relationship defined by CT volume 5 0.94 3 QSM volume (r 5 0.98) was derived from all pre-and posttreatment images. Figure 2D shows good agreement in volume measurement between CT and QSM images. In addition, the correspondence between paramagnetic susceptibility of hematoma regions in QSM and high Hounsfield unit (HU) values in CT is supported by a linear correlation (r 5 0.37, P 5 0.016) (Fig. S2A in the supplementary  material) . No significant correlation was found between volume measurement and estimated magnetic susceptibility (Fig. S2B) . Figure 3 shows the hematoma volume and susceptibility change following treatment in a 15-year-old male patient. The hemorrhage size was 4.7 cm 3 and 3.31 cm 3 measured on QSM images of pre-and posttreatment, respectively. The corresponding mean magnetic susceptibility values were 0.28 ppm and 0.10 ppm. Both volume and magnetic susceptibility decreased in response to the treatment. Figure 4 shows another representative case in a 55-year-old man; the pretreatment hematoma volume was 7.65 cm 3 and posttreatment volume was 7.53 cm 3 measured on QSM images. However, the corresponding mean magnetic susceptibility values were 0.79 ppm to 0.64 ppm. Moreover, the hematoma regions exhibit a heterogeneous distribution of magnetic susceptibility, with more paramagnetic susceptibility values in the center than at the boundaries, as highlighted in the color maps in Figs. 3 and 4.
As shown in Fig. 5A , QSM-derived total volume did not decrease significantly between pre-and posttreatment scans (P > 0.5). However, considerable changes were found in the magnetic susceptibility following the treatment (Fig.  5B) . Figure 5A (bottom) and B (bottom) illustrate the changes in the total volume and mean magnetic susceptibility (from pre-to posttreatment scans), respectively, for each individual patient. The negative changes indicate that the total volumes of the hemorrhages slightly decreased in all 21 patients (Fig. 5A bottom) . In all but one patient, the mean magnetic susceptibility also decreased. One patient showed slightly increased mean magnetic susceptibility after treatment (Fig. 5B bottom) . A significant change of mean magnetic susceptibility across all patients was found between pre-and posttreatment imaging (P 5 0.004), but no significant change was found in the QSM-derived total volume (P 5 0.21). NIHSS measured on each individual patient is listed in Table 1 , and NIHSS changes following the treatment (posttreatment -pretreatment) are shown in Fig. 5C .
No significant correlation was found between hematoma volume and NIHSS changes following treatment, as shown in Fig. 6A ,B. No significant correlation was found between volume changes and QSM values changes (Fig. S3 in the supplementary material) . No significant correlation was found between CT values changes and NIHSS changes, as shown in Fig. S4 . However, significant positive correlations were observed between NIHSS changes and QSM values changes (Fig. 6C , r 5 0.8, P < 0.001) or QSM values percentage changes (Fig. 6D , r 5 0.71, P 5 0.003).
Discussion
The current study demonstrates that QSM offers excellent image contrast and is more sensitive than CT in the detection of hemorrhages. In addition, the volume of the hematomas determined on CT and QSM images was compared.
Comparison of mean magnetic susceptibility between preand posttreatment was also conducted in hematoma lesions and was correlated with corresponding NIHSS changes. This study led to several unique findings: 1) a high correlation of volume measurement on CT and QSM with highly linear relationship; 2) magnetic susceptibility decreased significantly following treatment, while no significant changes were found in hematoma volume; 3) the susceptibility values changes following treatment were significantly positively correlated with NIHSS changes.
Robust volume measurement is important on an individual-patient level because hematoma size correlates with hematoma growth and is associated with early neurological deterioration and treatment outcome. 37 However, the apparent size of hemorrhage lesions on magnitude GRE MRI and CT are not equal because of the underlying differences in the imaging modalities. Previous studies on hematoma have shown that CT volume 5 0.8* GRE volume. 38 QSM, which is insensitive to the parameter-dependent blooming artifacts seen in GRE magnitude images, provides a reliable measurement that is independent of imaging parameters to reveal the tissue properties. Wang et al 15 measured the hematoma volume using QSM and showed magnitude volume/QSM volume 5 1.24. 15 Our results show a strong correlation between lesion volume measured on CT and QSM with a highly linear relationship. The relative underestimation of the volume measured on CT compared to that measured on QSM is caused by the insensitivity of CT to the presence of small hemorrhage lesions. This suggests that QSM offers a more reliable measurement in hematoma volume than CT.
In the patients who underwent the posttreatment imaging, mean susceptibility in the hemorrhages derived from QSM decreased following the treatment. While this result suggests that QSM is a promising means of measuring treatment efficacy, the aging of the hemorrhagic lesion may be a potentially confounding issue. Previous studies observed that the susceptibility values monotonically increased with time in an in vitro human blood phantom. 28 However, another study showed that the susceptibility decreased from acute to late subacute ICH. 27 The susceptibility changes following the treatment may also be admixed with changes related to the natural evolution of hematoma susceptibility over time. However, a recent study on monitoring microhemorrhage magnetic susceptibility changes reported that the susceptibility decreased over time: -0.1 6 0.14 ppb per day. 39 Therefore, the observed susceptibility value change varying from -10 ppb up to -260 ppb are mainly attributed to treatment. We show, for the first time, to our knowledge, that the magnetic susceptibility of hemorrhages decreases following the hematoma treatment. The measured magnetic susceptibility reduction following the hematoma treatment reflects a lower concentration of methemoglobin. This finding may indicate the clearance of methemoglobin by effective treatments such as surgical drainage or medications that significantly dilute the concentration of methemoglobin. Because iron in hemorrhage is the most concentrated in the center, the smaller the volume drawn, the larger the mean susceptibility is. Therefore, the volume of the ICH is negatively correlated with the mean magnetic susceptibility for a specific lesion. Sun et al 40 reported that the mean susceptibility of ICH in different disease stages over a 2D ROI was up to 1.8 ppm similar to those of 4-day and older blood clot phantom reported by Chang et al, 27 which is almost as double as our measurements. However, Chang et al 27 measured the susceptibility values (0.45-0.8 ppm) of blood clot phantom over a 3D ROI in the first 4 hours, which is consistent with our measurements on ICH patients at hyperacute/acute stage. Gho et al 28 reported that the mean susceptibility values of in vitro human blood increased from 0.1 ppm at the start to 0.6 ppm at 8 days. The reported susceptibility values of the blood phantoms at hyperacute/acute stage were less than 1 ppm. 27, 28 There are variations in the measured susceptibility values of hematoma lesions in the literature. A subjective bias on the manual segmentation of the hematoma volumes on a single 2D slice or over a 3D volume could also contribute the discrepancy. Further correlation of susceptibility values changes with NIHSS changes suggests that QSM is an effective means to monitor treatment. However, a good correlation between magnetic susceptibility and other clinical measures needs to be established in the future. In particular, more effort should be made to investigate the magnetic susceptibility changes specific to different treatments, such as surgical drainage or medications, for certain hematomas.
In this study, a major limitation was the limited number of patients who underwent follow-up imaging examinations. In future studies, this method will need to be replicated in a larger patient population. Furthermore, by correlating hematoma with regional brain volumes, abnormalities such as fiber discontinuities or hyperintensities on T 2 -weighted fluid attenuation inversion recovery images, will facilitate investigation of the hematoma.
In conclusion, we found that QSM-derived magnetic susceptibility of hematoma decreased following treatment, while volume did not, suggesting a more effective means to monitor hematoma treatment. Characterization of magnetic susceptibility of hematoma lesions, brain tissue, and vasculature may allow better understanding and management of hematoma expansion and would be important in developing and applying hemorrhage therapy. QSM offers a more direct way to quantify the magnetic susceptibility of blood products, and may become an essential part of a hemorrhage MRI protocol and the method of choice clinically to monitor hematoma treatment.
